Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions

P. C. Kao, G. G. Klee, R. L. Taylor, H. Heath

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

We developed and validated a radioimmunoassay for circulating human parathyroid hormone-related peptide (PTHrP), based on a commercial antiserum to the synthetic 1-34 fragment of PTHrP, 125I-Tyr°-PTHrP(1-34) as radioligand, and prior extraction of the native peptide from plasma with C-2 cartridges. We determined immunoreactive PTHrP concentrations in plasma samples from 48 healthy persons (mean±SD, 3.1±1.0 pmol/liter; range, less than 2 to 5 pmol/liter), 8 patients with primary hyperparathyroidism, 36 patients with hypercalcemia and a concurrent malignant lesion, and 9 normocalcemic patients with cancer and increased serum levels of carcinoembryonic antigen or prostate-specific antigen. PTHrP was normal in samples from patients with primary hyperparathyroidism (3.2 ± 1.1 pmol/liter), secondary hyperparathyroidism (2.5±1.3 pmol/liter), and cancer without hypercalcemia (2.4±1.0 pmol/liter). In contrast, plasma immunoreactive PTHrP levels were increased (6.0 to 85.0 pmol/liter) in 47% of patients with hypercalcemia and cancer of various types, with or without bone metastatic lesions. Large amounts of PTHrP were also found in conditioned medium from cultured human prostatic carcinoma cells. Thus, PTHrP may be a causative factor for hypercalcemia associated with a malignant lesion in at least half of the cases. Measurement of circulating PTHrP may be of differential diagnostic help in hypercalcemic states.

Original languageEnglish (US)
Pages (from-to)1399-1407
Number of pages9
JournalMayo Clinic Proceedings
Volume65
Issue number11
StatePublished - 1990

Fingerprint

Parathyroid Hormone-Related Protein
Hypercalcemia
Primary Hyperparathyroidism
Neoplasms
Secondary Hyperparathyroidism
Carcinoembryonic Antigen
Prostate-Specific Antigen
Conditioned Culture Medium
Parathyroid Hormone
Radioimmunoassay
Immune Sera
Carcinoma
Bone and Bones
Peptides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kao, P. C., Klee, G. G., Taylor, R. L., & Heath, H. (1990). Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions. Mayo Clinic Proceedings, 65(11), 1399-1407.

Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions. / Kao, P. C.; Klee, G. G.; Taylor, R. L.; Heath, H.

In: Mayo Clinic Proceedings, Vol. 65, No. 11, 1990, p. 1399-1407.

Research output: Contribution to journalArticle

Kao, PC, Klee, GG, Taylor, RL & Heath, H 1990, 'Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions', Mayo Clinic Proceedings, vol. 65, no. 11, pp. 1399-1407.
Kao, P. C. ; Klee, G. G. ; Taylor, R. L. ; Heath, H. / Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions. In: Mayo Clinic Proceedings. 1990 ; Vol. 65, No. 11. pp. 1399-1407.
@article{2b05c8e14a004bd5be7f2e5befa6c620,
title = "Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions",
abstract = "We developed and validated a radioimmunoassay for circulating human parathyroid hormone-related peptide (PTHrP), based on a commercial antiserum to the synthetic 1-34 fragment of PTHrP, 125I-Tyr°-PTHrP(1-34) as radioligand, and prior extraction of the native peptide from plasma with C-2 cartridges. We determined immunoreactive PTHrP concentrations in plasma samples from 48 healthy persons (mean±SD, 3.1±1.0 pmol/liter; range, less than 2 to 5 pmol/liter), 8 patients with primary hyperparathyroidism, 36 patients with hypercalcemia and a concurrent malignant lesion, and 9 normocalcemic patients with cancer and increased serum levels of carcinoembryonic antigen or prostate-specific antigen. PTHrP was normal in samples from patients with primary hyperparathyroidism (3.2 ± 1.1 pmol/liter), secondary hyperparathyroidism (2.5±1.3 pmol/liter), and cancer without hypercalcemia (2.4±1.0 pmol/liter). In contrast, plasma immunoreactive PTHrP levels were increased (6.0 to 85.0 pmol/liter) in 47{\%} of patients with hypercalcemia and cancer of various types, with or without bone metastatic lesions. Large amounts of PTHrP were also found in conditioned medium from cultured human prostatic carcinoma cells. Thus, PTHrP may be a causative factor for hypercalcemia associated with a malignant lesion in at least half of the cases. Measurement of circulating PTHrP may be of differential diagnostic help in hypercalcemic states.",
author = "Kao, {P. C.} and Klee, {G. G.} and Taylor, {R. L.} and H. Heath",
year = "1990",
language = "English (US)",
volume = "65",
pages = "1399--1407",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions

AU - Kao, P. C.

AU - Klee, G. G.

AU - Taylor, R. L.

AU - Heath, H.

PY - 1990

Y1 - 1990

N2 - We developed and validated a radioimmunoassay for circulating human parathyroid hormone-related peptide (PTHrP), based on a commercial antiserum to the synthetic 1-34 fragment of PTHrP, 125I-Tyr°-PTHrP(1-34) as radioligand, and prior extraction of the native peptide from plasma with C-2 cartridges. We determined immunoreactive PTHrP concentrations in plasma samples from 48 healthy persons (mean±SD, 3.1±1.0 pmol/liter; range, less than 2 to 5 pmol/liter), 8 patients with primary hyperparathyroidism, 36 patients with hypercalcemia and a concurrent malignant lesion, and 9 normocalcemic patients with cancer and increased serum levels of carcinoembryonic antigen or prostate-specific antigen. PTHrP was normal in samples from patients with primary hyperparathyroidism (3.2 ± 1.1 pmol/liter), secondary hyperparathyroidism (2.5±1.3 pmol/liter), and cancer without hypercalcemia (2.4±1.0 pmol/liter). In contrast, plasma immunoreactive PTHrP levels were increased (6.0 to 85.0 pmol/liter) in 47% of patients with hypercalcemia and cancer of various types, with or without bone metastatic lesions. Large amounts of PTHrP were also found in conditioned medium from cultured human prostatic carcinoma cells. Thus, PTHrP may be a causative factor for hypercalcemia associated with a malignant lesion in at least half of the cases. Measurement of circulating PTHrP may be of differential diagnostic help in hypercalcemic states.

AB - We developed and validated a radioimmunoassay for circulating human parathyroid hormone-related peptide (PTHrP), based on a commercial antiserum to the synthetic 1-34 fragment of PTHrP, 125I-Tyr°-PTHrP(1-34) as radioligand, and prior extraction of the native peptide from plasma with C-2 cartridges. We determined immunoreactive PTHrP concentrations in plasma samples from 48 healthy persons (mean±SD, 3.1±1.0 pmol/liter; range, less than 2 to 5 pmol/liter), 8 patients with primary hyperparathyroidism, 36 patients with hypercalcemia and a concurrent malignant lesion, and 9 normocalcemic patients with cancer and increased serum levels of carcinoembryonic antigen or prostate-specific antigen. PTHrP was normal in samples from patients with primary hyperparathyroidism (3.2 ± 1.1 pmol/liter), secondary hyperparathyroidism (2.5±1.3 pmol/liter), and cancer without hypercalcemia (2.4±1.0 pmol/liter). In contrast, plasma immunoreactive PTHrP levels were increased (6.0 to 85.0 pmol/liter) in 47% of patients with hypercalcemia and cancer of various types, with or without bone metastatic lesions. Large amounts of PTHrP were also found in conditioned medium from cultured human prostatic carcinoma cells. Thus, PTHrP may be a causative factor for hypercalcemia associated with a malignant lesion in at least half of the cases. Measurement of circulating PTHrP may be of differential diagnostic help in hypercalcemic states.

UR - http://www.scopus.com/inward/record.url?scp=0025226082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025226082&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 1399

EP - 1407

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -